首页> 外国专利> THERAPEUTIC AGENT COMPRISING HUMANIZED ANTI EPIREGULIN ANTIBODY AS ACTIVE INGREDIENT FOR NON SMALL CELL LUNG CARCINOMA EXCLUDING ADENOCARCINOMA

THERAPEUTIC AGENT COMPRISING HUMANIZED ANTI EPIREGULIN ANTIBODY AS ACTIVE INGREDIENT FOR NON SMALL CELL LUNG CARCINOMA EXCLUDING ADENOCARCINOMA

机译:包含人源化抗表皮生长素抗体的治疗剂,作为腺癌除外的非小细胞肺癌的有效成分

摘要

The present inventors succeeded in producing: an anti Epiregulin antibody exhibiting a cross species reactivity between a non human animal crab eating monkey and a human animal; an anti Epiregulin antibody with suppressed chemical decomposition; an anti Epiregulin antibody having a lowered isoelectric point; an anti Epiregulin antibody having an elevated thermal denaturation midpoint temperature; and an anti Epiregulin antibody having a reduced amount of aggregates by appropriately substituting an amino acid residue in the variable region sequence of a humanized EP27 antibody that is capable of exhibiting a cytotoxic activity and neutralization activity on a cancer cell said cancer cell expressing human Epiregulin to thereby inhibit the proliferation of the cancer cell. Also the present inventors succeeded in creating a therapeutic agent for non small cell lung carcinoma excluding adenocarcinoma said therapeutic agent comprising one of the aforesaid antibodies as an active ingredient.
机译:本发明人成功地产生了:在非人类食蟹的猴子和人类动物之间表现出交叉物种反应性的抗上皮调节蛋白抗体;具有抗化学分解作用的抗上皮调节蛋白抗体;等电点降低的抗上皮调节蛋白抗体;具有升高的热变性中点温度的抗上皮调节蛋白抗体;通过在人源化的EP27抗体的可变区序列中适当取代氨基酸残基的具有减少的聚集体的抗上皮调节蛋白抗体,所述EP27抗体能够对癌细胞表现出细胞毒活性和中和活性,所述表达人上皮调节蛋白的癌细胞从而抑制癌细胞的增殖。本发明人还成功地创建了用于除腺癌以外的非小细胞肺癌的治疗剂,所述治疗剂包含前述抗体之一作为活性成分。

著录项

  • 公开/公告号IN201617001389A

    专利类型

  • 公开/公告日2016-07-29

    原文格式PDF

  • 申请/专利权人

    申请/专利号IN201617001389

  • 申请日2016-01-14

  • 分类号A61K39/00;C07K16/22;C12P21/08;C12N15/09;C07K16/30;A61P35/00;A61K39/395;A61P43/00;C07K16/46;

  • 国家 IN

  • 入库时间 2022-08-21 14:24:46

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号